Adherence Rules Complicate the CBD Jaw-Pain Trial’s Analysis Label

The jaw-pain paper described an intention-to-treat analysis while also stating that follow-up visits were excluded when reported adherence fell below 80%. Both statements matter when determining which observations contributed to its results.

The report describes assignment and visit availability

The authors said primary analyses followed original treatment assignment and included all randomized subjects. Elsewhere, the methods state that participants attested to daily intake at monthly follow-up and that the corresponding visit was excluded if reported compliance for that interval was below 80%.

The paper also reports participants without follow-up and removals for screening errors. These details caution against using the analysis label alone as a complete description of the analyzed data.

The rule does not identify the direction of bias

Adherence was self-reported rather than established by a measured CBD concentration. From the rule alone, one cannot infer how many visits were removed in each group or whether excluding them favored CBD, the comparator or neither.

Those questions require the participant flow, visit-level denominators and handling of missing observations. A sensitivity analysis retaining or otherwise accounting for excluded observations would address a different question from simply repeating the “intention-to-treat” description.

Retain the reported clinical result

The trial did not demonstrate a significant between-group pain advantage for its 20 mg daily CBD regimen. The adherence qualification neither creates a hidden benefit nor proves the null result was caused by nonadherence. It clarifies what additional information is needed to assess the robustness of this small human trial.

Related analysis: the CBD jaw-pain trial’s pain and function results.

Research cited

Reeve and colleagues (2026), Oral Cannabidiol in the Treatment of Myofascial Pain Disorder of the Temporomandibular Region: A Placebo-Controlled Randomized Clinical Trial. DOI: 10.1159/000551040.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

The HGN Comparison Did Not Validate a Standalone Cannabis Impairment Test

The HGN analysis compared small groups defined by self-reported duration. It did not establish a standalone diagnostic accuracy for identifying cannabis-impaired drivers. What the statistical comparison involved Forty-four participants underwent horizontal gaze nystagmus assessment, with forty-three examined at three hours after smoking. The paper compared HGN incidence at that time…

Spread the love

Read Article: The HGN Comparison Did Not Validate a Standalone Cannabis Impairment Test

Stratified Cannabis Duration Patterns Coexisted With a Null Overall Correlation

The paper described an inverse pattern after grouping participants by self-reported duration, while its unstratified correlation between baseline blood THC and duration was nonsignificant. Both findings belong in an accurate account. The two analyses asked related questions differently Baseline blood measurements were available for sixty-four participants. The authors divided participants…

Spread the love

Read Article: Stratified Cannabis Duration Patterns Coexisted With a Null Overall Correlation

Percent-of-Maximum Cannabis Ratings Did Not Compare Absolute Severity

The paper’s average percent-of-maximum curve normalized each participant to that person’s own highest self-rating. Equal percentages on that graph did not necessarily mean equal absolute symptom severity across participants. The denominator was personal Wurz and DeGregorio summarized self-assessments from seventy-four participants after cannabis smoking. Each person’s ratings were expressed relative…

Spread the love

Read Article: Percent-of-Maximum Cannabis Ratings Did Not Compare Absolute Severity

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us